Decision on optimal combinatorial Therapies in IMIDS using Systems Approaches

Project Overview

DoCTIS is an EU-funded translational project aimed at addressing the urgent need to discover effective therapeutic strategies for immune-mediated inflammatory diseases.


Biomedical research partners from five different European countries as well as from the United States of America are collaborating toward this.

Work Packages

The DoCTIS project is structured in nine different work packages, involving animal model, patient, systems biology and clinical evaluation stages.


DoCTIS is the acronym for the EU-funded project entitled “Decision on Combinatorial Therapies in Immune-Mediated diseases using Systems approaches”. DoCTIS is a multicentric project involving diverse basic, applied and clinical research centres from Spain, Sweden, Italy, Germany, UK and USA aimed at improving treatment efficacy in six Immune-Mediated Inflammatory Diseases (IMIDs), encompassing: Crohn’s disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis. Through the generation of high volumes of data using of modern high-throughput technologies on samples from well-characterized IMID patients, and the use of advanced systems biology analytical approaches, we aim to identify therapeutic combinations that are much more efficacious and safer than current single-drug approaches.


Follow the most recent activity generated from the DoCTIS project.


See DoCTIS in the media and published work derived from the project.


Calendar of future and past events associated to the DoCTIS project.


If you are a patient suffering from an IMID, click here to know more on how the research at the DoCTIS project is working to help you.

Different patients can react differently to the same medication, their individual biological make-up determining how their body handles a drug. EU-funded research is advancing the tailoring of medication for a better fit.



We have begun a series of interviews with the scientists behind the project. We start with an interview with the coordination team of the project: Dra. Sara Marsal and Antonio Juliá. Read it now👉

The @DoctisEU project has been working to reach the stablished milestones. Check ou the “Milestones in combinatorial therapies” on our website now 👉

NIH ACTIV-1 clinical trial on immunomodulators for severe #COVID19 is out! In line with our prediction, #abatacept reduces the risk of death

Learn about the recent advances of the project partners by reading the new scientific publication “A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets”👉

Load More…